Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.65 |
| ▸ | KLK7 | P49862 | 1/20 | 0.65 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.59 |
| ▸ | PPARA | Q07869 | 3/20 | 0.57 |
| ▸ | SYK | P43405 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 4/20 | 0.54 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | PPARG | P37231 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | TACR1 | P25103 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9943562 | 0.95 | KLK5 (0.65) | KLK5KLK7CACNA1BPPARASYK | |
| SCHEMBL9943561 | 0.95 | KLK5 (0.65) | KLK5KLK7CACNA1BPPARASYK | |
| SCHEMBL10585294 | 0.95 | KLK5 (0.65) | KLK5KLK7CACNA1BPPARASYK | |
| SCHEMBL12585497 | 0.95 | KLK5 (0.65) | KLK5KLK7CACNA1BPPARASYK | |
| SCHEMBL25491606 | 0.94 | KLK7 (0.59) | KLK5KLK7CACNA1BPPARASYK | |
| SCHEMBL17659960 | 0.94 | KLK5 (0.62) | KLK5KLK7CACNA1BPPARASYK | |
| SCHEMBL5419241 | 0.94 | KLK7 (0.59) | KLK5KLK7CACNA1BPPARASYK | |
| SCHEMBL20481004 | 0.94 | CACNA1B (0.59) | KLK5KLK7CACNA1BPPARASYK | |
| SCHEMBL5870038 | 0.94 | KLK5 (0.64) | KLK5KLK7CACNA1BPPARASYK | |
| SCHEMBL20144655 | 0.94 | CACNA1B (0.59) | KLK5KLK7CACNA1BPPARASYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| EP-0303602-A4 | ENZYMATIC SYNTHESIS. | COMMW SCIENT IND RES ORG (AU) | 1990-06-26 | — | — | EP | disclosed |
| EP-0303602-A1 | ENZYMATIC SYNTHESIS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1989-02-22 | — | — | EP | disclosed |
| WO-1987006268-A1 | ENZYMATIC SYNTHESIS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH OR (AU) | 1987-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | CTSE, SPINT2, CTSF | KLK5 1520/4885KLK7 1937/4885CACNA1B 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.